Hematologic Analysis of Paritaprevir (ABT-450)/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I

METHODS


tenofovir, emtricitabine, atazanavir, and other trials of direct-acting antiviral treatment in co-infected patients.

CONCLUSIONS

The absolute rates of adverse events may be lower for the RBV than lower margin suppressive effects on hematologic parameters, even in patients with advanced cirrhosis or in patients experiencing an adverse event and with a physician visit, the decision should be left to the treating physician.

REFERENCES


DISCLOSURES

The abstracts presented at the Annual Meeting of the American Society for Clinical Investigation are embargoed and will not be made available online until after the meeting. The embargo on these abstracts is Friday, September 4, 2014, 11:59 PM EST. These abstracts will be released to the public online after the embargo date.

To obtain a QR code reader, go to your device app store and search for an app for reading QR codes.

For more information, please visit www.obvianews.com/abstracts.